icon
0%

Regeneron Pharmaceuticals REGN - News Analyzed: 8,518 - Last Week: 100 - Last Month: 400

↑ Regeneron's REGN: A Rollercoaster of Insider Sales, Robust Q3 and Rising Valuations

Facebook WhatsApp Reddit X (aka Twitter) Copy Link
Back
Regeneron's REGN: A Rollercoaster of Insider Sales, Robust Q3 and Rising Valuations
Regeneron Pharmaceuticals' shares(NASDAQ:REGN) have recently experienced significant activity. Insider Christine Poon sold 6,500 shares, while Pinnacle Associates, Amalgamated Bank, Wealthfront Advisers, AlphaQuest, Oak Grove Capital, General American Investors, and Nisa Investment Advisors all reduced their stakes. Despite this, banks and other investors have been increasing their positions, highlighting the mixed perception. The firm delivered a strong Q3 with earnings beating expectations, despite a major tax hit. Its product, Eylea, has been resubmitted for approval and the successful drug Dupixent continues its rally.

J.P. Morgan, BMO Capital, Canaccord Genuity, and others have maintained their buy rating amidst rising price targets, even when Eylea faces headwinds. Positive results from multiple late-stage trials, approvals on Libtayo, and success in phase 3 Garetosmab trial have bolstered the attractiveness of the company making it a value buy. The firm also enjoyed a formidable Q3 with Dupixent, counterbalancing Eylea weakness.

However, Regeneron has experienced a fall in its stock, stimulating engaging debates around its valuation.

Please note that this is a synopsis of newsworthy events and should not be used as financial advice.

Regeneron Pharmaceuticals REGN News Analytics from Thu, 07 Aug 2025 07:00:00 GMT to Sat, 01 Nov 2025 20:44:43 GMT - Rating 7 - Innovation 3 - Information 8 - Rumor 2

Facebook WhatsApp Reddit X (aka Twitter) Copy Link
The email address you have entered is invalid.